Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

Contributing sentiments towards policy:

54% : "Today's new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare.
49% : The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.
46% : The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says.
45% : Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.